INTRODUCTION
There are currently more than 1.3 billion tobacco smokers in the world according to the World Health Organization (WHO) (1) . It has been demonstrated that cigarette smoking is the most important risk factor for the development and progression of chronic obstructive pulmonary disease (COPD), and accounts for about 80% of COPD cases (2, 3) .
COPD, a term referring to two respiratory system diseases: chronic bronchitis and emphysema, is characterized by an airflow limitation that is not fully reversible. The airflow limitation is usually both progressive and related to the abnormal inflammatory response of the lungs to inhaled noxious particles or gases (4, 5) .
It has been reported that 10% to 15% of all smokers (6) and up to 26% of heavy smokers develop COPD (7) . As the prevalence of smoking has risen among females and decreased slightly among males, the sexual distribution of COPD 
Conclusions, further questions and outlook
As indicated earlier, smoking leads to irreversible lung emphysema and heart hypertrophy. The inflammatory process in the airways and lungs of COPD patients caused by cigarette smoke exposure were only partially reversed after smoking cessation.
There still needs to be an increase in the awareness of smoking cessation for patients with other disorders such as cardiovascular diseases, however, the following factors should be of focus for tobacco control in the following groups/classes of patients:
younger in age, low socio-economic status, patients with smoking family members, patients with a higher body mass index, and higher total family income.
In conclusion, it is now clear that smoking cessation should be considered as a first step to halt in the decline and progression of lung emphysema, inflammation, and oxidative stress. An additional medication and support could be provided to tackle chronic respiratory symptoms involving inflammation (See table 1). 
